Perspective: Lessons learned from molecular genetic studies of thyroid cancer - Insights into pathogenesis and tumor-specific therapeutic targets

被引：45
作者：
Fagin, JA [1 ]
机构：
[1] Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Sci, Cincinnati, OH 45267 USA
来源：
ENDOCRINOLOGY | 2002年 / 143卷 / 06期
关键词：
D O I：
10.1210/en.143.6.2025
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2025 / 2028
页数：4
相关论文
共 46 条
[1]   Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma [J].
Bongarzone, I ;
Fugazzola, L ;
Vigneri, P ;
Mariani, L ;
Mondellini, P ;
Pacini, F ;
Basolo, F ;
Pinchera, A ;
Pilotti, S ;
Pierotti, MA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :2006-2009
[2]   MOLECULAR CHARACTERIZATION OF A THYROID TUMOR-SPECIFIC TRANSFORMING SEQUENCE FORMED BY THE FUSION OF RET TYROSINE KINASE AND THE REGULATORY SUBUNIT RI-ALPHA OF CYCLIC AMP-DEPENDENT PROTEIN KINASE-A [J].
BONGARZONE, I ;
MONZINI, N ;
BORRELLO, MG ;
CARCANO, C ;
FERRARESI, G ;
ARIGHI, E ;
MONDELLINI, P ;
DELLAPORTA, G ;
PIEROTTI, MA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :358-366
[3]   High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation [J].
Bounacer, A ;
Wicker, R ;
Caillou, B ;
Cailleux, AF ;
Sarasin, A ;
Schlumberger, M ;
Suarez, HG .
ONCOGENE, 1997, 15 (11) :1263-1273
[4]   PTEN expression is reduced in a subset of sporadic thyroid carcinomas:: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 [J].
Bruni, P ;
Boccia, A ;
Baldassarre, G ;
Trapasso, F ;
Santoro, M ;
Chiappetta, G ;
Fusco, A ;
Viglietto, G .
ONCOGENE, 2000, 19 (28) :3146-3155
[5]   Molecular basis of Hurthle cell papillary thyroid carcinoma [J].
Cheung, CC ;
Ezzat, S ;
Ramyar, L ;
Freeman, JL ;
Asa, SL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :878-882
[6]  
CROYLE ML, IN PRESS 84 ANN M EN
[7]   Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma [J].
Demetri, GD ;
Fletcher, CDM ;
Mueller, E ;
Sarraf, P ;
Naujoks, R ;
Campbell, N ;
Spiegelman, BM ;
Singer, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3951-3956
[8]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[9]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[10]  
FUGAZZOLA L, 1995, CANCER RES, V55, P5617
12345